Glycidamide Promotes the Growth and Migratory Ability of Prostate Cancer Cells by Changing the Protein Expression of Cell Cycle Regulators and Epithelial-to-Mesenchymal Transition (EMT)-Associated Proteins with Prognostic Relevance

Titus I. Ekanem1,2, Chi-Chen Huang3,4, Ming-Heng Wu4,1, Ding-Yen Lin5,6, Wen-Fu T. Lai7,8,9 and Kuen-Haur Lee6,10,*

1Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica
2Department of Hematology, University of Uyo, Uyo, Nigeria
3Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
4Graduate Institute of Translational Medicine, Taipei Medical University, Taipei, Taiwan.
5Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan
6Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
7McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA, United States of America
8Department of Research, Taipei Medical University/Shuang-Ho Hospital, New Taipei City, Taiwan
9Department of Dentistry, Taipei Medical University/Shuang-Ho Hospital, New Taipei City, Taiwan
10Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

†These authors contributed equally to this work.

* Correspondence: Dr. Kuen-Haur Lee, Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, No. 250 Wu-Hsing Street, Taipei 11031, Taiwan. Tel: +886-2-27361661 ext. 7627, Fax: +886-2-66387537, E-mail: khlee@tmu.edu.tw
Supplementary Material

**Figure S1.** Survival analysis of prostate cancer patients with SurvExpress (n=140). Low expression of CCND1 (A), CDK4 (B), and TWIST1 (C) were correlated with good prognosis of prostate cancer patients. High expression of SNAI1 (D), SNAI2 (E), and CDH1 (F) were correlated with good prognosis of prostate cancer patients.

**Figure S2.** Kaplan–Meier curves according to any two-gene models. Clinical outcomes for the combinations of CDK4/TWIST1 (A), CDK4/SNAI2 (B), and TWIST1/SNAI2 (C) mRNA status of prostate cancer patients.
Supplementary Fig. 1
Supplementary Fig. 2